NCT00351767已完成2 期
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 170
- 主要终点
- Skin re-epithelialization without drainage or dressing requirements
研究概览
简要总结
This is a Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of three different doses of topically applied telbermin in subjects ≥ 18 years old with diabetic foot ulcers. Approximately 160 adult subjects with Type 1 or Type 2 diabetes mellitus will be enrolled at approximately 40 investigational sites in the United States and Canada.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability and willingness to comply with the following: study drug gel application and dressing changes as instructed; use offloading footwear and practice of rubbing prevention (shear injury) of the study ulcer for the duration of the study; adherence to study requirements or use of adequate caregiver assistance
- •For males and females of childbearing potential, use of an effective method of contraception
- •Type 1 or 2 diabetes mellitus
- •Inability to perceive 10 grams pressure in the peri-ulcer area using a Semmes-Weinstein 5.07 monofilament
- •At least one full thickness (i.e., extending into the subcutaneous tissue or beyond) ulcer of the foot at or below the malleolus that does not involve bone, tendons, ligaments, or muscle (University of Texas Classification System for Diabetic Foot Wounds, Stage 1a)
- •Estimated foot ulcer surface area, L x W, between ≥ 0.70 cm^2 and ≤ 5.0 cm^2 as measured at Treatment Day 1 Any subject who does not meet this criterion will not be eligible for randomization.
- •Eye examination (indirect ophthalmoscopy, fundus photography, or fluorescein angiography) within 6 months prior to randomization with no indication of proliferative diabetic retinopathy or wet age-related macular degeneration
排除标准
- •Presence of an active systemic or local cancer or tumor of any kind (with the exception of non-melanoma skin cancer)
- •Proliferative diabetic retinopathy or wet age-related macular degeneration
- •A history of pulmonary edema
- •Active congestive heart failure
- •Active infection or cellulitis of any ulcer on the study foot
- •Active osteomyelitis of the study foot
- •Active connective tissue disease
- •Study ulcers with an etiology not related to diabetes (e.g., thermal, chemical, radiation insult)
- •History of active Charcot foot of the study foot within 6 months of screening
- •Treatment with systemic corticosteroids (equivalent to > 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents within 14 days prior to the first study drug gel application or likelihood to receive one of these therapies during study participation
- •Previous or current radiation therapy to the distal lower extremity or likelihood to receive this therapy during study participation
- •Pregnancy or lactation
- •Presence of more than two full-thickness ulcers on the study foot
- •End-stage renal failure necessitating chronic hemodialysis or chronic ambulatory peritoneal dialysis
- •Poor nutritional status
- •Life expectancy of less than 3 years (in the opinion of the investigator)
- •Known hypersensitivity to any ingredients of telbermin, placebo, or vehicle, including excipients in the formulation of telbermin or placebo gel
- •Known prior inability to complete required study visits during study participation
- •A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the investigator, may pose a threat to subject compliance
- •Use of a platelet-derived growth factor within the 28 days prior to screening
- •Use of any investigational drug or therapy within the 28 days prior to screening
研究组 & 干预措施
1
Experimental
干预措施: telbermin (Drug)
2
Experimental
干预措施: telbermin (Drug)
3
Experimental
干预措施: telbermin (Drug)
4
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Skin re-epithelialization without drainage or dressing requirements
时间窗: 12 weeks
次要结局
- Complete closure of the study ulcer(24 weeks)
- Durability of closure(Time to recurrence)
- Change and percent change in ulcer surface area(12 and 24 weeks)
- Number of debridements performed(12 weeks)
研究者
相似试验
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS SubjectsAcute Ischemic StrokeNCT05403866Lumosa Therapeutics Co., Ltd.89
终止
2 期
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary GeneralizationRefractory EpilepsyNCT04153175Cerebral Therapeutics LLC30
招募中
2 期
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsLupus NephritisNCT05039619Hoffmann-La Roche40
已完成
2 期
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft RecipientsCytomegalovirus InfectionsNCT01753167Genentech, Inc.122
已完成
2 期
A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate TherapyRheumatoid ArthritisNCT01242917Amgen159